Immune Hemolytic Anemia and Renal Failure Due to Teniposide

Publisher Website
Google Scholar
Abstract
TENIPOSIDE (VM 26) is a semisynthetic derivative of podophyllotoxin (molecular weight, 657 daltons) that has been used for a decade in cancer chemotherapy, especially in lymphoma and brain tumors. The drug has been reported to cause anaphylactic reactions of unknown origin.1 This paper describes clinical and immunohematologic features of an antibody to teniposide that causes acute hemolysis and renal failure.Case HistoryTeniposide therapy was initiated in a 47-year-old man who had a relapse a few months after removal of a brain tumor. The drug was given monthly at a dose of 100 mg per day on Days 1 and . . .